Tokito, T., Kolesnik, O., Sørensen, J., Artac, M., Quintela, M. L., Lee, J., . . . Butts, C. (2024). Epacadostat plus pembrolizumab versus placebo plus pembrolizumab as first-line treatment for metastatic non-small cell lung cancer with high levels of programmed death-ligand 1: A randomized, double-blind phase 2 study. BMC.
Chicago Style (17th ed.) CitationTokito, Takaaki, et al. Epacadostat Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as First-line Treatment for Metastatic Non-small Cell Lung Cancer with High Levels of Programmed Death-ligand 1: A Randomized, Double-blind Phase 2 Study. BMC, 2024.
MLA (9th ed.) CitationTokito, Takaaki, et al. Epacadostat Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as First-line Treatment for Metastatic Non-small Cell Lung Cancer with High Levels of Programmed Death-ligand 1: A Randomized, Double-blind Phase 2 Study. BMC, 2024.